Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.548 -0.032 (-2.03%)

Streaming Delayed Price Updated: 11:26 AM EDT, Mar 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

March 20, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics's Return On Capital Employed Overview ↗

March 14, 2023

Via Benzinga

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 09, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Preview: Lineage Cell Therapeutics's Earnings ↗

March 08, 2023

Via Benzinga

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

March 02, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

March 06, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

February 22, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology ↗

February 22, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell...

Via Benzinga

Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

February 08, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

November 29, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

November 28, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 10, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Preview: Lineage Cell Therapeutics ↗

November 09, 2022

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

November 03, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

October 31, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via TheNewswire.com

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

By David Willey, Benzinga

Via News Direct

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗

October 13, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via Benzinga

Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

October 10, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa

October 04, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel

October 03, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗

October 03, 2022

Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.

Via Benzinga

The Three Best Anti-Aging Stocks to Buy in September ↗

September 19, 2022

These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments

Via InvestorPlace

Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗

September 07, 2022

According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78...

Via Benzinga

Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference

August 15, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Recap: Lineage Cell Therapeutics Q2 Earnings ↗

August 11, 2022

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.